Literature DB >> 23799735

Severe hyperkalemia during cardiopulmonary bypass: etiology and effective therapy.

David P Martin1, Daniel Gomez, Joseph D Tobias, William Schechter, Carlos Cusi, Robert Michler.   

Abstract

Hyperkalemia is considered a medical emergency as it can result in severe disturbances in cardiac rhythm and death. Although many causes of hyperkalemia exist, exogenous red blood cell transfusions are being recognized as the primary perioperative etiology. The authors report a case of severe intraoperative hyperkalemia associated with the use of allogeneic blood products (packed red blood cells), during a surgical mission to a developing country. The patient was undergoing repeat mitral valve replacement with cardiopulmonary bypass (CPB) and developed significant hyperkalemia with a serum potassium value of 9.9 mEq/L. Successful intraoperative therapies were instituted with a gradual reduction in the serum potassium value to 4.8 mEq, which allowed the patient to be weaned from CPB. The authors review the etiology of hyperkalemia in children including its relationship with allogeneic red blood cell transfusions and treatment modalities including specific therapies which can be instituted during CPB.

Entities:  

Keywords:  CPB; cardiopulmonary bypass (CPB); cell saver; electrophysiology; mitral valve replacement

Mesh:

Substances:

Year:  2013        PMID: 23799735     DOI: 10.1177/2150135112467213

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  2 in total

1.  Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass.

Authors:  Michele Heath; Karthik Raghunathan; Ian Welsby; Cory Maxwell
Journal:  J Extra Corpor Technol       Date:  2014-09

2.  Zero balance ultrafiltration using dialysate during nationwide bicarbonate shortage: a retrospective analysis.

Authors:  Ryan Mullane; Lance Fristoe; Nicholas W Markin; Tara R Brakke; Helen Mari Merritt-Genore; Aleem Siddique; Clifford D Miles; Troy J Plumb
Journal:  J Cardiothorac Surg       Date:  2019-09-10       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.